Product Description: BAY-888 is a selective CK1α/CSNK1A1 (casein kinase 1α) ATP-competitive inhibitor (IC50: 4 nM@10 μM ATP; 63 nM@1 mM ATP). BAY-888 blocks the negative regulation of p53 and other signaling pathways by CK1α, induces apoptosis and inhibits proliferation of tumor cells. BAY-888 has shown inhibitory efficacy against cancers such as acute myeloid leukemia (AML) in PRISM barcoded cell line screening and can mimic the effects of shRNA-mediated CK1α knockdown. BAY-888 is primarily used for the development of anticancer drugs for p53 wild-type tumors and for the study of the mechanisms of CK1α-related signaling pathways[1][2][3].
Applications: Cancer-programmed cell death
Formula: C28H26FN5O2
References: [1]Preparation of 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-C]pyridin-4-ones as CSNK1 inhibitors. World Intellectual Property Organization, WO2020161257 A1 2020-08-13./[2]Steven M. Corsello, et al Abstract 3588: Discovery of potent and selective CSNK1A1 inhibitors for solid tumor therapy. Cancer Res 15 June 2022; 82 (12_Supplement): 3588./[3]Huang L, et al. Development of Oral, Potent, and Selective CK1α Degraders for AML Therapy. JACS Au. 2024 Nov 8;4(11):4423-4434.
CAS Number: 2468783-75-5
Molecular Weight: 483.54
Compound Purity: 98.35
Research Area: Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Casein Kinase
Deutsch
English
